{"prompt": "['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '7.4.', 'Pharmacodynamics (PD)', '87', '7.5.', 'Anti-Drug Antibodies (ADA)', '87', '8. STATISTICS', '87', '8.1.', 'Determinations of Sample Size', '87', '8.2.', 'Analysis Populations', '88', '8.3.', 'Patient Disposition, Characteristics and Concomitant Medication', '88', '8.4.', 'Statistical Methods', '88', '8.4.1.', 'Primary Endpoint Analyses', '88', '8.4.2.', 'Secondary Endpoint Analyses', '89', '8.4.3.', 'Tertiary Endpoint Analyses', '89', '8.5.', 'Interim Analyses', '91', '9. QUALITY CONTROL AND QUALITY ASSURANCE', '91', '9.1.', \"Investigator's Responsibility\", '91', '9.2.', 'Quality Control of Data', '92', '9.3.', 'Monitoring', '92', '9.4.', 'Data Management', '93', '9.5.', 'Quality Assurance Audit', '94', '10. ETHICS', '94', '10.1.', 'Institutional Review Board or Independent Ethics Committee', '94', '10.2.', 'Ethical Conduct of the Trial', '95', '10.3.', 'Patient Information and Informed Consent', '95', '10.4.', 'Patient Data Protection', '96', '11. TRIAL ADMINISTRATION', '96', '11.1.', 'Data Handling and Record Keeping', '96', '11.2.', 'Direct Access to Source Data/Documents', '96', '11.3.', 'Investigator Information', '97', '11.3.1. Investigator Obligations', '97', '11.3.2.', 'Protocol Signatures', '97', '11.3.3.', 'Publication Policy', '97', 'argenx BVBA', 'Confidential', 'Page 36 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', '11.3.4. Financing and Insurance', '98', '12. REFERENCES', '99', '13. APPENDICES', '101', 'LIST OF TABLES', 'Table 1', 'General Schedule of Assessments', '28', 'Table 2', 'Schedule of Assessments for Patients who Discontinued Early from Randomized', 'Treatment', '31', 'LIST OF FIGURES', 'Figure 1', 'Trial Design', '32', 'LIST OF APPENDICES', 'Appendix 1 Myasthenia Gravis-Activities of Daily Living', '101', 'Appendix 2 Quantitative Myasthenia Gravis Score', '102', 'Appendix 3 Myasthenia Gravis Composite Scale', '103', 'Appendix 4 Revised Version of 15-Item Quality of Life Scale for Myasthenia Gravis (MG-QoL15r)', '104', 'Appendix 5 EQ-5D-5L (UK English Sample Version)', '105', 'Appendix 6 Laboratory Evaluations', '107', 'Appendix 7 CCI', 'Appendix 8 Decision Tree for Re-treatment - Part A', '109', 'Appendix 9 Decision Tree for Re-treatment - Part B', '110', 'argenx BVBA', 'Confidential', 'Page 37 of 110']['11 July 2019', 'ARGX-113-1704', 'ARGX-113', 'Protocol Version 3.0, Final', 'LIST OF ABBREVIATIONS', 'Ab', 'Antibody', 'ABDEGTM', 'Antibody that enhances IgG degradation', 'AChE', 'Acetylcholinesterase', 'AChR', 'Acetylcholine receptor', 'ADA', 'Anti-drug antibodies', 'ADL', 'Activities of daily living', 'ADR', 'Adverse drug reaction', 'AE', 'Adverse event', 'ANCOVA', 'Analysis of covariance', 'CI', 'Confidence interval', 'CIOMS', 'Council for International Organizations of Medical Sciences', 'Cmax', 'Maximum observed serum concentration', 'CRO', 'Contract research organization', 'CTCAE', 'Common Terminology Criteria for Adverse Events', 'CTR', 'Clinical trial report', 'DSMB', 'Data Safety Monitoring Board', 'ECG', 'Electrocardiogram', 'eCRF', 'electronic Case Report Form', 'EDC', 'Electronic data capture', 'EoS', 'End of Study', 'EoT', 'End of Treatment', 'EQ-5D-5L', 'EuroQoL 5 Dimensions 5 Levels', 'Fc', 'Fragment, crystallized', 'FcRn', 'neonatal Fc Receptor', 'FDA', 'Food and Drug Administration', 'FSH', 'Follicle-Stimulating Hormone', 'FU', 'Follow-up', 'GCP', 'Good Clinical Practice', 'gMG', 'Generalized myasthenia gravis', 'HBV', 'Hepatitis B virus', 'HCV', 'Hepatitis C virus', 'HIV', 'Human immunodeficiency virus', 'IB', 'Investigator brochure', 'ICF', 'Informed consent form', 'ICH', 'International Council for Harmonization', 'IEC', 'Independent Ethics Committee', 'IgG', 'Immunoglobulin G', 'IMP', 'Investigational medicinal product', 'argenx BVBA', 'Confidential', 'Page 38 of 110']\n\n###\n\n", "completion": "END"}